Home/Clearside Biomedical/George Lasezkay

GL

George Lasezkay

President and Chief Executive Officer

Clearside Biomedical

Therapeutic Areas

Ophthalmology Retinal Diseases

Clearside Biomedical Pipeline

Drug	Indication	Phase
CLS-AX (axitinib injectable suspension)	Wet Age-Related Macular Degeneration (AMD)	Phase 3 Ready
XIPERE® (triamcinolone acetonide)	Macular Edema Associated with Uveitis	Approved
CLS-AX	Diabetic Macular Edema (DME)	Preclinical

Leadership Team at Clearside Biomedical

Charles A. Deignan

Chief Financial Officer

Thomas A. Ciulla

Chief Medical Officer

Benjamin R. Yerxa

Chief Technology Officer and Co-Founder

View full Clearside Biomedical profile